Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Argenx Se ADR (NQ: ARGX )

278.72 USD -2.06 (-0.73%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 19, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 138,052
Open 284.27
Bid (Size) 278.72 (12)
Ask (Size) 279.65 (2)
Prev. Close 280.78
Today's Range 278.34 - 289.88
52wk Range 248.21 - 382.15
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
argenx Highlights Strategic Priorities for 2022
argenx Highlights Strategic Priorities for 2022 
From Business Wire News Releases
What 8 Analyst Ratings Have To Say About argenx
Analysts have provided the following ratings for argenx (NASDAQ:ARGX) within the last quarter: Bullish Somewhat ... 
Tags Analyst Ratings ARGX Market News
From Benzinga

Performance

YTD
-20.61%
-20.61%
1 Month
-17.70%
-17.70%
3 Month
-5.84%
-5.84%
6 Month
-12.63%
-12.63%
1 Year
-2.89%
-2.89%

More News

Read More
argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis
From Business Wire News Releases
What 8 Analyst Ratings Have To Say About argenx
Tags BZI/AAR Benzinga Analyst Ratings
From Benzinga
Argenx's Vyvgart Wins FDA Approval For Autoimmune, Neuromuscular Disease
Tags General FDA ARGX
From Benzinga
A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street; Crude Oil Down 4%
Tags Global ORCL Futures
From Benzinga
5 Stocks To Watch For December 20, 2021
Tags Pre/Market Outlook Benzinga Market News
From Benzinga
The Week Ahead In Biotech (Dec. 19-25): Amgen And Aquestive Regulatory Decisions Key Events Of Holiday-Shortened Week
Tags IPOs AQST IMMX
From Benzinga
Is Argenx a Good Biotech Stock to Buy for 2022?
Tags Market News ARGX AZN
From Motley Fool
The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx
Tags Small Cap LYEL IBB
From Benzinga
2 Mid-Cap Biopharma Stocks BofA Securities Recommends For 2022
Tags Trading Ideas Analyst Color Biotech
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.